HLA-C and neoplasm: As a PD-1 blockade is dependent on T-cell recognition of tumour antigens, it may prove ineffective in cases where T cells lack TCRs corresponding to tumour antigens, where tumours fail to present antigens via their MHC, or where there is a lack of tumour-infiltrating lymphocytes (TILs) [21].